

MARKET REPORT



Multiple Myeloma -Epidemiology Forecast to 2027

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma -Epidemiology Forecast to 2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma -Epidemiology Forecast to 2027

DelveInsight's "Multiple Myeloma - Epidemiology Forecast, 2027" report provides a comprehensive analysis of the Multiple Myeloma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2016-2027

Multiple Myeloma Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Multiple Myeloma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Multiple Myeloma outlook. It also includes the explanation of changing trends of epidemiology outlining the Multiple Myeloma scenario.

Multiple Myeloma Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Multiple Myeloma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Multiple Myeloma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
- The Multiple Myeloma Report assesses the disease risk and burden and highlights the unmet needs
- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast
- 7MM Coverage
- Total Cases in Multiple Myeloma

<https://www.bioportfolio.co.uk/product/201671>
pdb@bioportfolio.co.uk to order

Key assessments

- Patient Segmentation in Multiple Myeloma
- Multiple Myeloma Risk & Burden
- Factors driving growth in a specific Multiple Myeloma patient population

Additional Details

Publisher : Delve Insight

Reference : DIEI0321

Number of Pages : 50

Report Format : PDF

Publisher Information :

The image is a promotional graphic for BioPortfolio. On the left, a person's head and shoulder are visible, holding a report cover. The report cover features the DelveInsight logo at the top, a cityscape with red cranes in the middle, and the BioPortfolio logo and text at the bottom. On the right, a hand in a blue glove is shown holding a pipette over a multi-well plate in a laboratory setting. The background is a bright, clean lab environment. Text on the right side includes the BioPortfolio logo, a description of services, a price guarantee, and the website URL.

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

- 1. Report Introduction2. Multiple Myeloma Epidemiology Overview at a Glance2.1. Patient Share Distribution of Multiple Myeloma in 20172.2. Patient Share Distribution of Multiple Myeloma in 20273. Disease Background and Overview: Multiple Myeloma3.1. Introduction3.2. Symptoms3.3. Etiology3.4. Risk Factors3.5. Pathophysiology3.6. Diagnosis3.7. Treatment4. Epidemiology and Patient Population4.1. Key Findings4.2. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM4.3. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM – By Countries5. Epidemiology of Multiple Myeloma by Countries5.1. United States5.1.1. Assumptions and Rationale5.1.2. Prevalent/Incident Cases of the Multiple Myeloma5.1.3. Sub-Type Specific cases of the Multiple Myeloma *5.1.4. Sex- Specific Cases of the Multiple Myeloma*5.1.5. Diagnosed Cases of the Multiple Myeloma5.2. EU5.3. Assumptions and Rationale5.4. Germany5.4.1. Assumptions and Rationale5.4.2. Prevalent/Incident Cases of the Multiple Myeloma5.4.3. Sub-Type Specific cases of the Multiple Myeloma*5.4.4. Sex- Specific Cases of the Multiple Myeloma*5.4.5. Diagnosed Cases of the Multiple Myeloma5.5. France5.5.1. Assumptions and Rationale5.5.2. Prevalent/Incident Cases of the Multiple Myeloma5.5.3. Sub-Type Specific cases of the Multiple Myeloma*5.5.4. Sex- Specific Cases of the Multiple Myeloma*5.5.5. Diagnosed Cases of the Multiple Myeloma5.6. Italy5.6.1. Assumptions and Rationale5.6.2. Prevalent/Incident Cases of the Multiple Myeloma5.6.3. Sub-Type Specific cases of the Multiple Myeloma*5.6.4. Sex- Specific Cases of the Multiple Myeloma*5.6.5. Diagnosed Cases of the Multiple Myeloma5.7. Spain5.7.1. Assumptions and Rationale5.7.2. Prevalent/Incident Cases of the Multiple Myeloma5.7.3. Sub-Type Specific cases of the Multiple Myeloma*5.7.4. Sex- Specific Cases of the Multiple Myeloma*5.7.5. Diagnosed Cases of the Multiple Myeloma5.8. United Kingdom5.8.1. Assumptions and Rationale5.8.2. Prevalent/Incident Cases of the Multiple Myeloma5.8.3. Sub-Type Specific cases of the Multiple Myeloma*5.8.4. Sex- Specific Cases of the Multiple Myeloma*5.8.5. Diagnosed Cases of the Multiple Myeloma5.9. Japan5.9.1. Assumptions and Rationale5.9.2. Prevalent/Incident Cases of the Multiple Myeloma5.9.3. Sub-Type Specific cases of the Multiple Myeloma*5.9.4. Sex- Specific Cases of the Multiple Myeloma*5.9.5. Diagnosed Cases of the Multiple Myeloma6. Unmet Needs of the Multiple Myeloma7. Appendix8. Report Methodology8.1. Sources9. DelveInsight Capabilities10. Disclaimer11. About DelveInsight*Indication Specific

List Of Tables in Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM

Table 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2027) *

Table 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2027)

List Of Figures, Charts and Diagrams in Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM

Table 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2027) *

Table 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2027)

How to Buy...

Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/201671>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3250** | Single User Price
- \$6500** | Site License Price
- \$9750** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.